The current S&P 500 P/E ratio is 25.50 (as of 1/18/17, end of day) – to compare with a mean P/E of 15.64 and median of 14.65 (sample data since 1870). Stocks are quite expensive – but we are NOT in a bubble, not yet anyhow, although we’re getting closer… Current S&P 500 PE Ratio: 25.50 +0.04 (0.18%) (4:10 pm EST, Wed Jan 18)
Price to earnings ratio, based on trailing twelve month “as reported” earnings. Current PE is estimated from latest reported earnings and current market price. No matter what – US rate hikes, global growth concerns, the volatility of oil and other commodities, Russia and China’s military ambitions, cybersecurity concerns, terrorist attacks, etc. – great companies will continue to thrive. If you are a long-term investor, buy opportunities are out there. Examples? Some energy issues (despite the sector’s recent advance) are still reasonably priced. No wonder Warren Buffett a few months back added to his Phillips 66 (PSX) holdings. Some biotech and healthcare issues seem to present investors with long-term appreciation potential. Think Biogen (BIIB) (An insider bought a massive amount of BIIB on 10/22 and 10/23/2015; shares still trade in the vicinity), Gilead Sciences, Inc. (GILD), Alnylam Pharmaceuticals (ALNY), Alexion Pharmaceuticals, Inc. (ALXN), and a few others. Financials may need to consolidate after their recent advance, but some retailers may also offer value. Think Bed Bath & Beyond Inc. (BBBY), J C Penney Company Inc (JCP), Macy’s, Inc. (M) (recently down), Michael Kors (KORS); just beware of value traps. Insiders have been buying Vera Bradley, Inc. (VRA) recently. Should you? Casino equities led by Wynn Resorts (WYNN) (which has consolidated over the past few months) may continue to outperform (after underperforming for years). Please, see below and our daily updates for insiders and hedge funds’ takes and many more ideas…
Recently or earlier this year insiders have bought shares of (new today) Kindred Biosciences Inc (KIN), Virtu Financial Inc (VIRT), American Outdoor Brands Corporation, formerly Smith & Wesson Holding Corporation (AOBC), Lawson Products, Inc. (LAWS), Mirati Therapeutics, Inc. (MRTX), WPX Energy Inc (WPX), Seritage Growth Properties (SRG), Regeneron Pharmaceuticals Inc (REGN), Retractable Technologies, Inc. (RVP), Dell Technologies Inc (DVMT), Loxo Oncology Inc (LOXO), Nicholas Financial, Inc. (NICK), Lions Gate Entertainment Corp. (LGF), Och-Ziff Capital Management Group LLC (OZM), Aquinox Pharmaceuticals Inc (AQXP), Daxor Corporation (DXR), FNB Bancorp (FNBG), Transenterix Inc (TRXC), Bonanza Creek Energy Inc (BCEI), Spark Energy Inc (SPKE), Celsius Holdings, Inc. (CELH), Versartis Inc (VSAR), Reata Pharmaceuticals Inc (RETA), Amicus Therapeutics, Inc. (FOLD), International Tower Hill Mines Ltd (THM), Och-Ziff Capital Management Group LLC (OZM), Infinity Pharmaceuticals Inc. (INFI), Vera Bradley, Inc. (VRA), Cadiz Inc (CDZI), tronc Inc (TRNC), formerly Tribune Publishing Company, Cesca Therapeutics Inc (KOOL), formerly ThermoGenesis Corp., Six Flags Entertainment Corp (SIX), Occidental Petroleum Corporation (OXY), Och-Ziff Capital Management Group LLC (OZM), Amicus Therapeutics, Inc (FOLD).
(The aforementioned list only includes a subset of companies where insider purchases have taken place; it is pre-screened by our in-house team of .o3 analysts along criteria that have yet to be determined!)
1. We are ourselves and nobody else but ourselves, which is us, so we are not responsible for the people who are not us and we are serious it’s not a joke. 2. We are not brokers we wanted to be brokers but there are exams and we can’t take too many exams because they are difficult and so we are not brokers nor do we intend to become brokers as long as there are exams. 3. We in no way claim that we have investigated or even considered or even tried to consider contemplating not to mention ignited a thought process revolving around the[...]